Publications by authors named "Roger Rittmaster"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

185,759

Total Likes

4,603

Extended Reach

193,929

Social Features

14
E
Effects of the oral testosterone undecanoate Kyzatrex™ on ambulatory blood pressure in hypogonadal men.
William B White, James S Bernstein, Roger Rittmaster, Om Dhingra

J Clin Hypertens (Greenwich)· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial.
Nallasivam Palanisamy, Alexi Tsodikov, Wei Yan, Khalid Suleman, Roger Rittmaster

Urol Oncol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Classic and International Society of Urological Pathology 2005 Modified Gleason grading using needle biopsies from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial.
M Scott Lucia, David G Bostwick, Matthew C Somerville, Ivy L Fowler, Roger S Rittmaster

Arch Pathol Lab Med· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genome-wide association study identifies genetic determinants of urine PCA3 levels in men.
Zhuo Chen, Jielin Sun, Seong-Tae Kim, Jack Groskopf, Junjie Feng, Roger S Rittmaster

Neoplasia· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genome-wide association study identifies loci at ATF7IP and KLK2 associated with percentage of circulating free PSA.
Guangfu Jin, Siqun Lilly Zheng, Hans Lilja, Seong-Tae Kim, Sha Tao, Roger S Rittmaster

Neoplasia· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial.
A Karim Kader, Jielin Sun, Brian H Reck, Paul J Newcombe, Seong-Tae Kim, Roger S Rittmaster

Eur Urol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genome-wide association study identifies a new locus JMJD1C at 10q21 that may influence serum androgen levels in men.
Guangfu Jin, Jielin Sun, Seong-Tae Kim, Junjie Feng, Zhong Wang, Roger S Rittmaster

Hum Mol Genet· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
Michael Marberger, Stephen J Freedland, Gerald L Andriole, Mark Emberton, Curtis Pettaway, Roger S Rittmaster

BJU Int· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study.
Jean-Alfred Thomas, Leah Gerber, Lionel L Bañez, Daniel M Moreira, Roger S Rittmaster

Cancer Epidemiol Biomarkers Prev· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.
Neil E Fleshner, M Scott Lucia, Blair Egerdie, Lorne Aaron, Gregg Eure, Roger S Rittmaster

Lancet· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of Bayesian and frequentist approaches to incorporating external information for the prediction of prostate cancer risk.
Paul J Newcombe, Brian H Reck, Jielin Sun, Greg T Platek, Claudio Verzilli, Roger S Rittmaster

Genet Epidemiol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study.
J Curtis Nickel, Claus Roehrborn, Francesco Montorsi, Timothy H Wilson, Roger S Rittmaster

J Urol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Claus G Roehrborn, J Curtis Nickel, Gerald L Andriole, R Paul Gagnier, Libby Black, Roger S Rittmaster

Urology· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
J Curtis Nickel, Peter Gilling, Teuvo L Tammela, Betsy Morrill, Timothy H Wilson, Roger S Rittmaster

BJU Int· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
Sheila M J Aubin, Jennifer Reid, Mark J Sarno, Amy Blase, Jacqueline Aussie, Roger S Rittmaster

Urology· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low serum testosterone levels are poor predictors of sexual dysfunction.
Michael Marberger, Timothy H Wilson, Roger S Rittmaster

BJU Int· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoprevention of prostate cancer.
Roger S Rittmaster

Acta Oncol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biopsy misidentification identified by DNA profiling in a large multicenter trial.
Michael Marberger, John D McConnell, Ivy Fowler, Gerald L Andriole, David G Bostwick, Roger S Rittmaster

J Clin Oncol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
Claus G Roehrborn, Gerald L Andriole, Timothy H Wilson, Ramiro Castro, Roger S Rittmaster

Eur Urol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
Gerald L Andriole, David Bostwick, Otis W Brawley, Leonard Gomella, Michael Marberger, Roger S Rittmaster

J Urol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.
Sheila M J Aubin, Jennifer Reid, Mark J Sarno, Amy Blase, Jacqueline Aussie, Roger Rittmaster

J Urol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate needle biopsy quality in reduction by dutasteride of prostate cancer events study: worldwide comparison of improvement with investigator training and centralized laboratory processing.
David G Bostwick, Junqi Qian, Krystyna Drewnowska, Stephen Varvel, Kathleen C Bostwick, Roger S Rittmaster

Urology· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial.
E David Crawford, Gerald L Andriole, Michael Marberger, Roger S Rittmaster

Urology· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.
Mary-Ellen Taplin, Meredith M Regan, Yoo-Joung Ko, Glenn J Bubley, Stephen E Duggan, Roger Rittmaster

Clin Cancer Res· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis